MICHAEL FRUMOVITZ to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications MICHAEL FRUMOVITZ has written about Antineoplastic Agents, Immunological.
Connection Strength
0.222
-
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 09; 158(3):570-575.
Score: 0.091
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.089
-
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166.
Score: 0.022
-
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
Score: 0.020